Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
Total Valuation
Iterum Therapeutics has a market cap or net worth of $19.53M. The enterprise value is $59.27M.
Market Cap$19.53M
Enterprise Value$59.27M
Share Statistics
Iterum Therapeutics has 52,787,678 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,787,678
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Iterum Therapeutics’s return on equity (ROE) is 6.07 and return on invested capital (ROIC) is -45.54%.
Return on Equity (ROE)6.07
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-45.54%
Return on Capital Employed (ROCE)-0.69
Revenue Per Employee0.00
Profits Per Employee-2.75M
Employee Count9
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Iterum Therapeutics is ―. Iterum Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio-8.54
Price to Fair Value-8.54
Price to FCF-1.30
Price to Operating Cash Flow-1.04
PEG Ratio0.02
Income Statement
In the last 12 months, Iterum Therapeutics had revenue of 0.00 and earned -24.77M in profits. Earnings per share was -1.26.
Revenue0.00
Gross Profit-254.00K
Operating Income-18.70M
Pretax Income-24.53M
Net Income-24.77M
EBITDA-21.73M
Earnings Per Share (EPS)-1.26
Cash Flow
In the last 12 months, operating cash flow was -19.91M and capital expenditures -14.57K, giving a free cash flow of -19.93M billion.
Operating Cash Flow-19.91M
Free Cash Flow-19.93M
Free Cash Flow per Share-0.38
Dividends & Yields
Iterum Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.39
52-Week Price Change-79.21%
50-Day Moving Average0.54
200-Day Moving Average0.85
Relative Strength Index (RSI)32.85
Average Volume (3m)813.22K
Important Dates
Iterum Therapeutics upcoming earnings date is Mar 12, 2026, TBA (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateMar 12, 2026
Ex-Dividend Date―
Financial Position
Iterum Therapeutics as a current ratio of 1.41, with Debt / Equity ratio of 0.00%
Current Ratio1.41
Quick Ratio1.41
Debt to Market Cap1.31
Net Debt to EBITDA-0.99
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Iterum Therapeutics has paid 240.00K in taxes.
Income Tax240.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Iterum Therapeutics EV to EBITDA ratio is -2.59, with an EV/FCF ratio of -2.10.
EV to Sales0.00
EV to EBITDA-2.59
EV to Free Cash Flow-2.10
EV to Operating Cash Flow-2.10
Balance Sheet
Iterum Therapeutics has $11.00M in cash and marketable securities with $33.73M in debt, giving a net cash position of -$22.73M billion.
Cash & Marketable Securities$11.00M
Total Debt$33.73M
Net Cash-$22.73M
Net Cash Per Share-$0.43
Tangible Book Value Per Share-$1.21
Margins
Gross margin is -171.28%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-171.28%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Iterum Therapeutics is $5.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.50
Price Target Upside1386.49% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast62.61%